Summer Moon Capital Statement on FIRB Blocking of Mayne Pharma-Cosette Acquisition
Key Facts: FIRB’s preliminary decision to block Cosette Pharmaceuticals’ A$672 million acquisition of Mayne Pharma will cause hundreds of millions of dollars of unjustified losses to Australian shareholders The Adelaide manufacturing facility remains …